ImmunityBio Inc. (NASDAQ: IBRX) announced the U.S. Food and Drug Administration has accepted for review its supplemental biologics license application ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE